Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial
ABSTRACT Background There are no effective treatments for multiple system atrophy (MSA). Objective The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA. Methods This was a double‐blind, paralle...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2021-07, Vol.36 (7), p.1704-1711 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1711 |
|---|---|
| container_issue | 7 |
| container_start_page | 1704 |
| container_title | Movement disorders |
| container_volume | 36 |
| creator | Rascol, Olivier Cochen de Cock, Valérie Pavy‐Le Traon, Anne Foubert‐Samier, Alexandra Thalamas, Claire Sommet, Agnes Rousseau, Vanessa Perez‐Lloret, Santiago Fabbri, Margherita Azulay, Jean Philippe Corvol, Jean‐Christophe Couratier, Philippe Damier, Philippe Defebvre, Luc Durif, Franck Geny, Christian Houeto, Jean‐Luc Remy, Philippe Tranchant, Christine Verin, Marc Tison, François Meissner, Wassilios G. |
| description | ABSTRACT
Background
There are no effective treatments for multiple system atrophy (MSA).
Objective
The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA.
Methods
This was a double‐blind, parallel‐group, placebo‐controlled, randomized trial in patients with “probable” MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease–Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA‐Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score.
Results
A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (−2.13 units [95% confidence interval, CI, −4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12‐week in UMSARS Part II (exploratory outcome: −1.41 units [95% CI, −2.84; 0.03]; p = 0.05) and in MSA‐QoL emotional/social dimension (secondary outcome: −6.99 units [95% CI, −13.40; −0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo).
Conclusion
The MSA‐FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. © 2021 International Parkinson and Movement Disorder Society |
| doi_str_mv | 10.1002/mds.28569 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03190779v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2554576433</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4229-6916beac716ed9770ead3f5d45ac019f44129f755248b22ba039e884bcc6fc843</originalsourceid><addsrcrecordid>eNp10c1OGzEUBWCralVS6IIXQCN1QxcD_h3b7CJKSqVELBIWXVkej0cZ5IkH2wPNjkfoM_ZJ6jSUSpVYWbK-e-yrA8AxgmcIQnzeN_EMC1bJN2CCGEGlwIy_BRMoBCsJEuwAfIjxDkKEGKregwNCuMSSiQn4PnOj_2FTt7FF60OR1rZYbvsh-V6nzhSrYHXq7SYVvi0Wo0vd4HYiJtsX0xT8sN5eFKs8tVhOfz39nM1vb_JQp90ReNdqF-3H5_MQ3M6uVpfX5fzm67fL6bw0FGNZVhJVtdWGo8o2knNodUNa1lCmDUSypRRh2XLGMBU1xrWGRFohaG1M1RpBySH4vM9da6eG0PU6bJXXnbqeztXuDhIkIefyAWV7urdD8PejjUn1XTTWOb2xfowKswxJHsCZfvqP3vkxbPImWTHKeEUJ-fe4CT7GYNuXHyCodt2o3I360022J8-JY93b5kX-LSOD8z147Jzdvp6kFl-W-8jfVGGW3w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2554576433</pqid></control><display><type>article</type><title>Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Rascol, Olivier ; Cochen de Cock, Valérie ; Pavy‐Le Traon, Anne ; Foubert‐Samier, Alexandra ; Thalamas, Claire ; Sommet, Agnes ; Rousseau, Vanessa ; Perez‐Lloret, Santiago ; Fabbri, Margherita ; Azulay, Jean Philippe ; Corvol, Jean‐Christophe ; Couratier, Philippe ; Damier, Philippe ; Defebvre, Luc ; Durif, Franck ; Geny, Christian ; Houeto, Jean‐Luc ; Remy, Philippe ; Tranchant, Christine ; Verin, Marc ; Tison, François ; Meissner, Wassilios G.</creator><creatorcontrib>Rascol, Olivier ; Cochen de Cock, Valérie ; Pavy‐Le Traon, Anne ; Foubert‐Samier, Alexandra ; Thalamas, Claire ; Sommet, Agnes ; Rousseau, Vanessa ; Perez‐Lloret, Santiago ; Fabbri, Margherita ; Azulay, Jean Philippe ; Corvol, Jean‐Christophe ; Couratier, Philippe ; Damier, Philippe ; Defebvre, Luc ; Durif, Franck ; Geny, Christian ; Houeto, Jean‐Luc ; Remy, Philippe ; Tranchant, Christine ; Verin, Marc ; Tison, François ; Meissner, Wassilios G. ; MSA-FLUO Study Group ; for the MSA‐FLUO Study Group</creatorcontrib><description>ABSTRACT
Background
There are no effective treatments for multiple system atrophy (MSA).
Objective
The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA.
Methods
This was a double‐blind, parallel‐group, placebo‐controlled, randomized trial in patients with “probable” MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease–Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA‐Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score.
Results
A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (−2.13 units [95% confidence interval, CI, −4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12‐week in UMSARS Part II (exploratory outcome: −1.41 units [95% CI, −2.84; 0.03]; p = 0.05) and in MSA‐QoL emotional/social dimension (secondary outcome: −6.99 units [95% CI, −13.40; −0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo).
Conclusion
The MSA‐FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. © 2021 International Parkinson and Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.28569</identifier><identifier>PMID: 33792958</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Antidepressants ; Atrophy ; Emotions ; Fluoxetine ; fluoxetine; multiple system atrophy; clinical trial; placebo; symptomatic treatment ; Life Sciences ; Medical treatment ; Movement disorders ; Neurodegenerative diseases ; Parkinson's disease ; Patients ; Placebos ; Quality of life ; Serotonin uptake inhibitors</subject><ispartof>Movement disorders, 2021-07, Vol.36 (7), p.1704-1711</ispartof><rights>2021 International Parkinson and Movement Disorder Society</rights><rights>2021 International Parkinson and Movement Disorder Society.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4229-6916beac716ed9770ead3f5d45ac019f44129f755248b22ba039e884bcc6fc843</citedby><cites>FETCH-LOGICAL-c4229-6916beac716ed9770ead3f5d45ac019f44129f755248b22ba039e884bcc6fc843</cites><orcidid>0000-0002-6460-4319 ; 0000-0001-9069-6512 ; 0000-0003-2172-7527 ; 0000-0003-3869-0564 ; 0000-0002-1410-6397 ; 0000-0001-7325-0199</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.28569$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.28569$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33792958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03190779$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Rascol, Olivier</creatorcontrib><creatorcontrib>Cochen de Cock, Valérie</creatorcontrib><creatorcontrib>Pavy‐Le Traon, Anne</creatorcontrib><creatorcontrib>Foubert‐Samier, Alexandra</creatorcontrib><creatorcontrib>Thalamas, Claire</creatorcontrib><creatorcontrib>Sommet, Agnes</creatorcontrib><creatorcontrib>Rousseau, Vanessa</creatorcontrib><creatorcontrib>Perez‐Lloret, Santiago</creatorcontrib><creatorcontrib>Fabbri, Margherita</creatorcontrib><creatorcontrib>Azulay, Jean Philippe</creatorcontrib><creatorcontrib>Corvol, Jean‐Christophe</creatorcontrib><creatorcontrib>Couratier, Philippe</creatorcontrib><creatorcontrib>Damier, Philippe</creatorcontrib><creatorcontrib>Defebvre, Luc</creatorcontrib><creatorcontrib>Durif, Franck</creatorcontrib><creatorcontrib>Geny, Christian</creatorcontrib><creatorcontrib>Houeto, Jean‐Luc</creatorcontrib><creatorcontrib>Remy, Philippe</creatorcontrib><creatorcontrib>Tranchant, Christine</creatorcontrib><creatorcontrib>Verin, Marc</creatorcontrib><creatorcontrib>Tison, François</creatorcontrib><creatorcontrib>Meissner, Wassilios G.</creatorcontrib><creatorcontrib>MSA-FLUO Study Group</creatorcontrib><creatorcontrib>for the MSA‐FLUO Study Group</creatorcontrib><title>Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial</title><title>Movement disorders</title><addtitle>Mov Disord</addtitle><description>ABSTRACT
Background
There are no effective treatments for multiple system atrophy (MSA).
Objective
The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA.
Methods
This was a double‐blind, parallel‐group, placebo‐controlled, randomized trial in patients with “probable” MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease–Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA‐Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score.
Results
A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (−2.13 units [95% confidence interval, CI, −4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12‐week in UMSARS Part II (exploratory outcome: −1.41 units [95% CI, −2.84; 0.03]; p = 0.05) and in MSA‐QoL emotional/social dimension (secondary outcome: −6.99 units [95% CI, −13.40; −0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo).
Conclusion
The MSA‐FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. © 2021 International Parkinson and Movement Disorder Society</description><subject>Antidepressants</subject><subject>Atrophy</subject><subject>Emotions</subject><subject>Fluoxetine</subject><subject>fluoxetine; multiple system atrophy; clinical trial; placebo; symptomatic treatment</subject><subject>Life Sciences</subject><subject>Medical treatment</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Parkinson's disease</subject><subject>Patients</subject><subject>Placebos</subject><subject>Quality of life</subject><subject>Serotonin uptake inhibitors</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10c1OGzEUBWCralVS6IIXQCN1QxcD_h3b7CJKSqVELBIWXVkej0cZ5IkH2wPNjkfoM_ZJ6jSUSpVYWbK-e-yrA8AxgmcIQnzeN_EMC1bJN2CCGEGlwIy_BRMoBCsJEuwAfIjxDkKEGKregwNCuMSSiQn4PnOj_2FTt7FF60OR1rZYbvsh-V6nzhSrYHXq7SYVvi0Wo0vd4HYiJtsX0xT8sN5eFKs8tVhOfz39nM1vb_JQp90ReNdqF-3H5_MQ3M6uVpfX5fzm67fL6bw0FGNZVhJVtdWGo8o2knNodUNa1lCmDUSypRRh2XLGMBU1xrWGRFohaG1M1RpBySH4vM9da6eG0PU6bJXXnbqeztXuDhIkIefyAWV7urdD8PejjUn1XTTWOb2xfowKswxJHsCZfvqP3vkxbPImWTHKeEUJ-fe4CT7GYNuXHyCodt2o3I360022J8-JY93b5kX-LSOD8z147Jzdvp6kFl-W-8jfVGGW3w</recordid><startdate>202107</startdate><enddate>202107</enddate><creator>Rascol, Olivier</creator><creator>Cochen de Cock, Valérie</creator><creator>Pavy‐Le Traon, Anne</creator><creator>Foubert‐Samier, Alexandra</creator><creator>Thalamas, Claire</creator><creator>Sommet, Agnes</creator><creator>Rousseau, Vanessa</creator><creator>Perez‐Lloret, Santiago</creator><creator>Fabbri, Margherita</creator><creator>Azulay, Jean Philippe</creator><creator>Corvol, Jean‐Christophe</creator><creator>Couratier, Philippe</creator><creator>Damier, Philippe</creator><creator>Defebvre, Luc</creator><creator>Durif, Franck</creator><creator>Geny, Christian</creator><creator>Houeto, Jean‐Luc</creator><creator>Remy, Philippe</creator><creator>Tranchant, Christine</creator><creator>Verin, Marc</creator><creator>Tison, François</creator><creator>Meissner, Wassilios G.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><general>Wiley</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-6460-4319</orcidid><orcidid>https://orcid.org/0000-0001-9069-6512</orcidid><orcidid>https://orcid.org/0000-0003-2172-7527</orcidid><orcidid>https://orcid.org/0000-0003-3869-0564</orcidid><orcidid>https://orcid.org/0000-0002-1410-6397</orcidid><orcidid>https://orcid.org/0000-0001-7325-0199</orcidid></search><sort><creationdate>202107</creationdate><title>Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial</title><author>Rascol, Olivier ; Cochen de Cock, Valérie ; Pavy‐Le Traon, Anne ; Foubert‐Samier, Alexandra ; Thalamas, Claire ; Sommet, Agnes ; Rousseau, Vanessa ; Perez‐Lloret, Santiago ; Fabbri, Margherita ; Azulay, Jean Philippe ; Corvol, Jean‐Christophe ; Couratier, Philippe ; Damier, Philippe ; Defebvre, Luc ; Durif, Franck ; Geny, Christian ; Houeto, Jean‐Luc ; Remy, Philippe ; Tranchant, Christine ; Verin, Marc ; Tison, François ; Meissner, Wassilios G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4229-6916beac716ed9770ead3f5d45ac019f44129f755248b22ba039e884bcc6fc843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antidepressants</topic><topic>Atrophy</topic><topic>Emotions</topic><topic>Fluoxetine</topic><topic>fluoxetine; multiple system atrophy; clinical trial; placebo; symptomatic treatment</topic><topic>Life Sciences</topic><topic>Medical treatment</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Parkinson's disease</topic><topic>Patients</topic><topic>Placebos</topic><topic>Quality of life</topic><topic>Serotonin uptake inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rascol, Olivier</creatorcontrib><creatorcontrib>Cochen de Cock, Valérie</creatorcontrib><creatorcontrib>Pavy‐Le Traon, Anne</creatorcontrib><creatorcontrib>Foubert‐Samier, Alexandra</creatorcontrib><creatorcontrib>Thalamas, Claire</creatorcontrib><creatorcontrib>Sommet, Agnes</creatorcontrib><creatorcontrib>Rousseau, Vanessa</creatorcontrib><creatorcontrib>Perez‐Lloret, Santiago</creatorcontrib><creatorcontrib>Fabbri, Margherita</creatorcontrib><creatorcontrib>Azulay, Jean Philippe</creatorcontrib><creatorcontrib>Corvol, Jean‐Christophe</creatorcontrib><creatorcontrib>Couratier, Philippe</creatorcontrib><creatorcontrib>Damier, Philippe</creatorcontrib><creatorcontrib>Defebvre, Luc</creatorcontrib><creatorcontrib>Durif, Franck</creatorcontrib><creatorcontrib>Geny, Christian</creatorcontrib><creatorcontrib>Houeto, Jean‐Luc</creatorcontrib><creatorcontrib>Remy, Philippe</creatorcontrib><creatorcontrib>Tranchant, Christine</creatorcontrib><creatorcontrib>Verin, Marc</creatorcontrib><creatorcontrib>Tison, François</creatorcontrib><creatorcontrib>Meissner, Wassilios G.</creatorcontrib><creatorcontrib>MSA-FLUO Study Group</creatorcontrib><creatorcontrib>for the MSA‐FLUO Study Group</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rascol, Olivier</au><au>Cochen de Cock, Valérie</au><au>Pavy‐Le Traon, Anne</au><au>Foubert‐Samier, Alexandra</au><au>Thalamas, Claire</au><au>Sommet, Agnes</au><au>Rousseau, Vanessa</au><au>Perez‐Lloret, Santiago</au><au>Fabbri, Margherita</au><au>Azulay, Jean Philippe</au><au>Corvol, Jean‐Christophe</au><au>Couratier, Philippe</au><au>Damier, Philippe</au><au>Defebvre, Luc</au><au>Durif, Franck</au><au>Geny, Christian</au><au>Houeto, Jean‐Luc</au><au>Remy, Philippe</au><au>Tranchant, Christine</au><au>Verin, Marc</au><au>Tison, François</au><au>Meissner, Wassilios G.</au><aucorp>MSA-FLUO Study Group</aucorp><aucorp>for the MSA‐FLUO Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov Disord</addtitle><date>2021-07</date><risdate>2021</risdate><volume>36</volume><issue>7</issue><spage>1704</spage><epage>1711</epage><pages>1704-1711</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><abstract>ABSTRACT
Background
There are no effective treatments for multiple system atrophy (MSA).
Objective
The objective of this study was to assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/d) for the symptomatic treatment of MSA.
Methods
This was a double‐blind, parallel‐group, placebo‐controlled, randomized trial in patients with “probable” MSA. The primary outcome was the change from baseline to week 12 in the mean total score of the Unified MSA Rating Scale (UMSARS Parts I + II). Secondary outcomes included change from baseline to week 6 in total UMSARS, and change from baseline to week 12 in the Scales for Outcomes in Parkinson Disease–Autonomic Dysfunction, Beck Depression Inventory, and different domains of the MSA‐Quality of Life Questionnaire. Exploratory outcomes included change from baseline to week 12 in the UMSARS Parts I and II separately and change from baseline to week 24 in the total UMSARS score.
Results
A total of 81 patients were randomly assigned, with no significant difference in the primary outcome (−2.13 units [95% confidence interval, CI, −4.55 to 0.29]; P = 0.08). There was a greater reduction on fluoxetine in the change from baseline to 12‐week in UMSARS Part II (exploratory outcome: −1.41 units [95% CI, −2.84; 0.03]; p = 0.05) and in MSA‐QoL emotional/social dimension (secondary outcome: −6.99 units [95% CI, −13.40; −0.56]; p < 0.03). A total of 5 deaths occurred (3 on fluoxetine and 2 on placebo).
Conclusion
The MSA‐FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation. © 2021 International Parkinson and Movement Disorder Society</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>33792958</pmid><doi>10.1002/mds.28569</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-6460-4319</orcidid><orcidid>https://orcid.org/0000-0001-9069-6512</orcidid><orcidid>https://orcid.org/0000-0003-2172-7527</orcidid><orcidid>https://orcid.org/0000-0003-3869-0564</orcidid><orcidid>https://orcid.org/0000-0002-1410-6397</orcidid><orcidid>https://orcid.org/0000-0001-7325-0199</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2021-07, Vol.36 (7), p.1704-1711 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_03190779v1 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Antidepressants Atrophy Emotions Fluoxetine fluoxetine multiple system atrophy clinical trial placebo symptomatic treatment Life Sciences Medical treatment Movement disorders Neurodegenerative diseases Parkinson's disease Patients Placebos Quality of life Serotonin uptake inhibitors |
| title | Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA‐FLUO Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A41%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fluoxetine%20for%20the%20Symptomatic%20Treatment%20of%20Multiple%20System%20Atrophy:%20The%20MSA%E2%80%90FLUO%20Trial&rft.jtitle=Movement%20disorders&rft.au=Rascol,%20Olivier&rft.aucorp=MSA-FLUO%20Study%20Group&rft.date=2021-07&rft.volume=36&rft.issue=7&rft.spage=1704&rft.epage=1711&rft.pages=1704-1711&rft.issn=0885-3185&rft.eissn=1531-8257&rft_id=info:doi/10.1002/mds.28569&rft_dat=%3Cproquest_hal_p%3E2554576433%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2554576433&rft_id=info:pmid/33792958&rfr_iscdi=true |